Patient Perspective on Testing – Survey Highlights
Survey highlights show that most GIST patients receive mutational testing, but awareness of ctDNA testing remains low despite strong interest.
Understanding Genomic Testing and SDH-Deficiency in Gastrointestinal Stromal Tumors (GISTs)
Understand why genetic testing is crucial for identifying and managing SDH-deficient GISTs, a rare and often hereditary tumor that requires specialized care.
New Collaborative Study on Genomic Testing in SDH‐Deficienct GIST
The LRG and the Pediatric & SDH-Deficient GIST Consortium published a paper this February on Genomic Testing in SDH-deficient GIST.
ESMO 2024 Summary
ESMO 2024 Summary
New Clinical Trials Focus for the LRG in 2024
Starting in January, every Wednesday will be dedicated learning about clinical trial process and to highlighting the groundbreaking clinical trials focused on gastrointestinal stromal tumors (GIST).
New Life Raft Group Paper Published
The LRG publishes, "Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry" Cancer Investigation ,Vol. 41, 2023. Issue 5 [...]
Progress in Precision Medicine for GIST Patients
These new data were presented by Dr. Sebastian Bauer and Dr. Breelyn A. Wilky during the 2023 January ASCO Plenary Series from the INTRIGUE Efficacy Results of ctDNA Analysis for GIST Patients.
Collaborative Effort Produces Position Paper on Need for Advanced Biomarker Testing
The Life Raft Group was recently part of team of authors on a collaborative position paper entitled 'Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type published' in Pathology: The Journal of the Royal College of Pathologists of Australia.
Changes to the Medical Update Forms
The Life Raft Group is committed to ensuring your GIST journey is as manageable as possible. We want to ensure that we expand our resources in order to help patients stay on their treatment longer by helping them to manage their side effects.
Increasing Survival without Borders
The Life Raft Group is pleased to announce the official establishment of our Regional Patient Registry, a partnership with Latin America, which will collect medical history and treatment information from more than 600 GIST patients who are represented by Fundación GIST Mexico, Fundación GIST Chile, and Pontificia Universidad Católica de Chile.